Cohort of Ischemic STROKE Patients

Study Overview
=================
Brief Summary
-----------------
Ischemic stroke is the first cause of acquired disability of the adult, the second cause of dementia and the third cause of death in the industrialized countries, what constitutes à major public health issue. Stroke is characterized by a cerebral parenchymal lesion due to an ischemic mechanism (85% of the cases) or hemorrhagic mechanism (15%). For a long time, the only approved treatment was the intravenous thrombolysis (rt-PA). Recently, thrombectomy has proven its superiority in this pathology. Cohorts of patients with stroke are rare but can be very valuable by their clinical, laboratory and imaging well documented. They are the source of new hypotheses for research or interventions as well as the quality of care assessment tool. The main objective of this project is to identify new markers: biological and imaging, treatment response and prognosis after ischemic stroke. Secondary objectives of the HIBISCUS-STROKE cohort are to establish a clinical database, completed by biological samples and by imaging data that can be used in the following areas: Descriptive epidemiology of ischemic stroke and cerebral reperfusion, Pharmacoepidemiology and treatments observatory: safety, efficacy, indication of treatment in real life, costs Assessment of the long-term effect of the treatment on the occurrence of disability, stroke recurrence and death, Quality of life and personal, familial, professional and social consequences of stroke, Research of new diagnostic and prognostic biomarkers, Research projects.

Official Title
-----------------
CoHort of Patients to Identify Biological and Imaging markerS of CardiovascUlar Outcomes in Stroke.

Conditions
-----------------
Ischemic Stroke

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age> 18 years Ischemic Stroke confirmed by MRI Proximal arterial occlusion (ICA or M1) Eligible for thrombolysis and/or thrombectomy Exclusion Criteria: Patients residing> 50 km from the Pierre Wertheimer Hospital (Lyon, France) Inability to perform the first sample (H0) Patient with progressive or uncontrolled cancer. Refusal to participate in the study or to sign the consent Lack of medical social coverage Deprivation of civil rights

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Degree of disability (mRS Score) | Degree of disability: modified Rankin Score | 5 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| infarct size | cerebral infarct size on MRI | day 6 | 
| Hemorrhagic transformation | Hemorrhagic transformation (ECASS scale) on imaging (CT or MRI) | 24 hours | 
| Neurological deficit | Neurological deficit NIH stroke Scale | up to 5 years | 
| Quality of life | QOL questionnaire | up to 5 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Ischemic stroke, stroke, bio-collection, Imaging markers, biomarkers, clinical outcomes